Hummingbird Diagnostics Gmbh

Comprehensive Biomarker Center Gmbh

Anke Wendschlag

Markus Beier

Andreas Keller

Eckart Meese

Petra Leidinger

Patrick Küry

Hans-Peter Hartung

Matthias Scheffler

Orhan Aktas

Jens Ingwersen

Timour Prozorovski

The present invention relates to methods of determining whether a patient responds to a therapeutic treatment of multiple sclerosis (MS), of monitoring the course of multiple sclerosis (MS) in a patient, of determining the risk for a relapse of multiple sclerosis (MS) in a patient, and of adjusting the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient. Said methods are based on the determination of the level of at least one miRNA in a test sample isolated from the patient. The present invention also relates to a method of identifying a compound suitable for the treatment of multiple sclerosis in a patient. Further, the present invention relates to the use of a polynucleotide or a polynucleotide set for detecting a miRNA to determine whether a patient responds to a therapeutic treatment of multiple sclerosis, to monitor the course of multiple sclerosis in a patient, to determine the risk of a relapse of multiple sclerosis in a patient, to adjust the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient, and to identify a compound suitable for the treatment of multiple sclerosis in a patient. Furthermore, the present invention relates to a kit for determining whether a patient responds to a therapeutic treatment of multiple sclerosis, for monitoring the course of multiple sclerosis in a patient, for determining the risk of a relapse of multiple sclerosis in a patient, for adjusting the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient, or for identifying a compound suitable for the treatment of multiple sclerosis in a patient comprising means for determining the level of at least one miRNA in a test sample isolated from a patient.

MiRNA based treatment monitoring in multiple sclerosis

The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of kidney cancer in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of kidney cancer in a body fluid sample from a subject. In addition, the present invention relates to sets of miRNAs for diagnosing and/or prognosing of kidney cancer in a body fluid sample from a subject.

Complex sets of miRNAs as non-invasive biomarkers for kidney cancer

Described herein are non-invasive methods, kits and means for diagnosing and/or prognosing of colon cancer a body fluid sample from a subject. Further described herein are sets of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of colon cancer in a body fluid sample from a subject. In addition, described herein are sets of miRNAs for diagnosing and/or prognosing of colon cancer in a body fluid sample from a subject.

Complex sets of miRNAs as non-invasive biomarkers for colon cancer

The present invention relates to non-invasive methods, kits and means for diagnosing and/or prognosing of colon cancer in a body fluid sample from a subject. Further, the present invention relates to set of polynucleotides or sets of primer pairs for detecting sets of miRNAs for diagnosing and/or prognosing of colon cancer in a body fluid sample from a subject. In addition, the present invention relates to sets of miRNAs for diagnosing and/or prognosing of colon cancer in a body fluid sample from a subject.

Growing community of inventors

Mannheim, Germany

Anke Wendschlag